Physician profile
Jenny E Queen
NPI 1437113578
$2,305.18
in general payments reported to CMS, 2019-2025
20 companies · $553 in 2025
The $553 reported for 2025 was more than what 82% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.21 · 2022: $559 · 2023: $331 · 2024: $766 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $649.92 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $345.11 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.72 | 2021-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $139.76 | 2023-2024 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $133.54 | 2022-2025 | Opsumit |
| Insmed, INC. | $107.57 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $89.45 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $86.90 | 2024-2025 | Glassia, Aralast |
| Merck Sharp & Dohme LLC | $80.65 | 2024-2025 | Winrevair |
| Pulmonx Corporation | $73.06 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $70.36 | 2022-2025 | Dupixent |
| Genzyme Corporation | $67.34 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $44.24 | 2022 | |
| Amgen INC. | $43.85 | 2023-2024 | Tezspire |
| Verona Pharma, INC. | $40.62 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $36.70 | 2021-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $31.24 | 2022 | |
| Viatris Specialty LLC | $18.67 | 2025 | Yupelri |
| Electromed, INC. | $17.08 | 2022 | |
| Pharming Healthcare, INC. | $15.40 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.